AbbVie Stock Climbs 1.19% Amid 89th-Ranked $900M Volume as Post-Humira Growth Fuels Renewed Investor Confidence

On August 29, 2025, AbbVie (ABBV) rose 1.19% with a trading volume of $0.90 billion, ranking 89th in market activity. The stock’s performance reflects renewed confidence in its post-Humira transition strategy and robust sales growth from key therapies.

AbbVie’s immunology segment continues to drive momentum, with Skyrizi and Rinvoq generating combined sales of $11.6 billion in H1 2025. Skyrizi’s annualized sales now approach $18 billion, while Rinvoq exceeds $8 billion. The company anticipates these therapies to exceed $25 billion in revenue in 2025, with further growth projected through 2027. Strong performance in neuroscience drugs, including Botox Therapeutic and migraine treatments, also contributed to a 20.3% year-over-year sales increase to $5 billion in H1 2025.

Despite progress, AbbVie faces challenges such as biosimilar competition for Humira and market saturation in Juvederm fillers. The company’s debt load remains elevated, with $63.0 billion in long-term obligations and a debt-to-capital ratio of 1.02, above the industry average. Strategic acquisitions have expanded its pipeline, but investors must weigh these against near-term risks like Imbruvica’s competitive pressures and potential revenue erosion in key markets.

Analyst estimates suggest AbbVie’s 2025 sales and EPS could grow by 7.5% and 18.9%, respectively, outpacing Merck’s projected 1.2% and 16.7%. The stock’s forward P/E ratio of 15.36 reflects higher valuation expectations compared to Merck’s 8.88, though both remain below peers like Eli Lilly. With no major patent expirations looming through 2029, AbbVie retains flexibility to invest in R&D and external innovation, positioning it for sustained growth.

Backtested results indicate that AbbVie’s stock has historically outperformed in periods of strong earnings revisions and product launches. The company’s ability to offset Humira’s decline through new therapies and disciplined cost management underscores its long-term resilience. However, debt management and market dynamics in key geographies remain critical factors for future performance.